No-Cost, No-Obligation Zantac Cancer Attorney Case Review

Antacid Cancer Attorney
Zantac Lawsuit News

Purity Certification May Have To Be Met If Zantac Could Ever Be Sold Again

The FDA could require licensed pharmacists to certify when a particular batch of drugs last passed a purity test as Valisure does

Wednesday, February 10, 2021 - Zantac and other heartburn and acid reflux drugs were too dangerous to be available over the counter. For decades consumers took Zantac only now to find out that it may have contained dangerously high levels of NDMA and that it may have caused their cancer. Thousands of individuals have registered to file claims against Sanofi, the maker of Zantac, for failing to test and warn them of the danger of Zantac causing cancer. Test trials may begin in 2021. If you have taken Zantac and developed cancer of the stomach, bladder, or other, you may wish to avail yourself of a free consultation with a Zantac Cancer Lawyer.

Experts are asking whether or not the FDA should require drug companies to publish an expiration date that and also data that shows the drug was tested and found to contain safe levels of N-nitrosodimethylamine (NDMA), a dangerous carcinogen. Carcinogenic levels of NDMA have been found in blood pressure, heartburn, and also drugs that are prescribed to treat diabetes. At the very least, pills should be taken from store shelves and put under the supervision of a prescribing doctor, and dispensed with the guidance of a pharmacist who could be made responsible for checking and ensuring that the expiration date was not exceeded. Patients should be advised by their doctors that dangerously high levels of NDMA have been found in the drug in the past. The Food and Drug Administration has set 96 nanograms per tablet or less as an acceptable level of NDMA. Recalls of metformin, the most popular drug given to patients to treat type 2 diabetes, have ensued.

Drug purity certification should be required for all drugs, not just ranitidine, and every pharmacy and drug store should be required to perform tests as does Valisure. Online drug testing pharmacy Valisure was the company that, in 2019, found dangerously high levels of NDMA in Zantac and other ranitidine tablets and alerted the US FDA and a recall was initiated. The company has also tested and found to be drugs used to treat hypertension and diabetes also are dangerous. The Valisure drug certification model should serve as the industry standard. Valisure is the first online drug testing pharmacy and provides its customers with a certificate if their drug meets purity standards. "Valisure provides consumers with increased safety, quality, and transparency in the medications it delivers at no additional cost. We test every batch of drugs, and your prescription arrives with a Certificate of Analysis from our lab" the company's website tells readers. The company also assures potential customers, "Valisure's mission is to independently check the chemical composition of medications before they reach consumers. Working with stakeholders throughout healthcare and the pharma supply chain, we deliver enhanced quality assurance to your patients and networks."

More Recent Heartburn MedicineLawsuit News:

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.

Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.